 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 921 | 回復(fù): 4 | ||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||
eileenshen新蟲 (初入文壇)
|
[求助]
求助大蝦幫我查找關(guān)于Diamyd公司產(chǎn)品diapep277的1、2、3期臨床報(bào)告
|
|
|
求助大蝦幫我查找關(guān)于Diamyd公司產(chǎn)品diapep277的1、2、3期臨床報(bào)告 這個(gè)藥剛剛完成三期臨床，萬(wàn)分感激！ 有pharmaprojects數(shù)據(jù)庫(kù)的盡量幫幫忙吧 |
回復(fù)此樓» 猜你喜歡
藥學(xué)學(xué)碩326求調(diào)劑
已經(jīng)有0人回復(fù)
-
26年博士申請(qǐng)
已經(jīng)有20人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有148人回復(fù)
-
求助 苯磷硫胺JP
已經(jīng)有0人回復(fù)
-
100金幣 阿莫西林克拉維酸鉀片BP藥典中提到的克拉維酸聚合物具體結(jié)構(gòu)式是啥？
已經(jīng)有2人回復(fù)
-
膳食補(bǔ)充劑合規(guī)性交流
已經(jīng)有0人回復(fù)
-
一志愿浙大藥學(xué)求調(diào)劑
已經(jīng)有0人回復(fù)
-
高溫高壓反應(yīng)求助
已經(jīng)有4人回復(fù)
-
藥學(xué)B區(qū)求調(diào)劑
已經(jīng)有0人回復(fù)
-
重慶醫(yī)科大學(xué)-人工智能醫(yī)學(xué)學(xué)院
已經(jīng)有0人回復(fù)
-
重慶醫(yī)科大學(xué)-人工智能醫(yī)學(xué)學(xué)院
已經(jīng)有0人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 求助28%的氨水PH多少
已經(jīng)有10人回復(fù)
- 求助 環(huán)酸酐與伯胺的開環(huán)閉環(huán)反應(yīng)
已經(jīng)有11人回復(fù)
- 求助：螯合反應(yīng)進(jìn)行程度的檢測(cè)方法？
已經(jīng)有4人回復(fù)
- 求助高手精修晶體
已經(jīng)有3人回復(fù)
- 【求助】用cDNA的ORF序列以基因組DNA為模板 做PCR 為何P不出其對(duì)應(yīng)的基因組序列?
已經(jīng)有8人回復(fù)
- 求助：拖尾的峰上面的峰
已經(jīng)有12人回復(fù)
- 求助羥基芍藥苷的結(jié)構(gòu)與抗氧化機(jī)理
已經(jīng)有3人回復(fù)
- 求助關(guān)于ACS投稿的版權(quán)協(xié)議
已經(jīng)有14人回復(fù)
- 碩士小妹的第一次SCI，各種求助
已經(jīng)有15人回復(fù)
- 求助，評(píng)閱人關(guān)于實(shí)驗(yàn)設(shè)計(jì)的的一個(gè)問題，為何不用正交實(shí)驗(yàn)
已經(jīng)有4人回復(fù)
- 帶孩子訪學(xué)的蟲友們求助！看看我們?cè)趺崔k？
已經(jīng)有17人回復(fù)
- 求助羊毛中的亞氨基（酰胺基）在什么情況下吸附氫離子
已經(jīng)有3人回復(fù)
- 求助sybyl關(guān)于添加形式電荷的問題
已經(jīng)有8人回復(fù)
- 投稿求助 關(guān)于highlights
已經(jīng)有4人回復(fù)
- 【討論和求助】金屬表面微區(qū)電極電位、相間電位的測(cè)量方法
已經(jīng)有7人回復(fù)
- 求大蝦指導(dǎo) 一個(gè)關(guān)于atoi函數(shù)的問題
已經(jīng)有3人回復(fù)
- 考研成績(jī)已出，求助
已經(jīng)有3人回復(fù)
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時(shí)
- 蟲號(hào): 674536
- 注冊(cè): 2008-12-14
- 性別: GG
- 專業(yè): 無(wú)神論
- 管轄: 人文社科
5樓2012-05-06 17:17:19
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時(shí)
- 蟲號(hào): 674536
- 注冊(cè): 2008-12-14
- 性別: GG
- 專業(yè): 無(wú)神論
- 管轄: 人文社科
【答案】應(yīng)助回帖
★
感謝參與，應(yīng)助指數(shù) +1
zhoudeli: 金幣+1, 多謝參與 2012-05-04 10:00:55
感謝參與，應(yīng)助指數(shù) +1
zhoudeli: 金幣+1, 多謝參與 2012-05-04 10:00:55
|
Detailed Information DiaPep227 (AVE-0277) is an hsp60-derived peptide, under development by Andromeda Biotech for the treatment and prevention of Type 1 diabetes (newly-diagnosed or established disease with some remaining endogenous insulin production) and latent adult autoimmune Type 2 diabetes (LADA). It acts by specific modulation of the autoimmune response from a proinflammatory (Th1) type to an anti-inflammatory (Th2) type to maintain residual β-cell function and halt disease progression (The Lancet, 24 Nov 2001, 358, 1749; Press release, Sanofi-Aventis, 19 Apr 2004; Company Web Page, Andromeda, 27 Oct 2008). Clinical Phase III Diabetes, Type 1 Teva A 1st double-blind, placebo-controlled Phase III trial in 456 patients in Europe, Israel and S Africa with newly-diagnosed Type 1 diabetes and LADA, to assess the safety and efficacy of DiaPep227, met its primary endpoint, defined as the change from baseline in C-peptide levels at the end of the study. Significant preservation of C-peptide was demonstrated in patients treated with DiaPep277 compared to the placebo arm. The decline in C-peptide levels was more pronounced in the placebo arm than in the treated group. The difference between the arms reached 0.949nmol/l/20min. This difference reflects a relative preservation of 23.4% compared to placebo. Evaluation of the primary endpoint was performed on patients in the modified ITT population who have at least one measurement post baseline. Additional analyses of clinical, efficacy and safety data from this study are ongoing (Press releases, Andromeda, 23 Jun 2008 & 8 Sep 2009 ; Press release, Andromeda, 22 Nov 2011, http://www.andromedabio.com/page.php?pageID=69). It is in a 2nd randomized, double-blind, placebo-controlled, parallel-group confirmatory Phase III trial (DIA-AID2) in 450 newly diagnosed Type 1 diabetics, in Austria, Belarus, Canada, Czech Republic, Finland, Germany, Hungary, Israel, Italy, Lithuania, Russia, Spain and the US, to assess DiaPep277 1mg sc x24mth on safety. The primary endpoint is beta cell preservation of function (Press release, Andromeda, 31 May 2010, http://www.andromedabio.com/page.php?pageID=56; Company Web Page, Andromeda, 5 May 2011, http://andromedabio.com/clinical_trials.php; ClinicalTrials.gov, 5 May 2011, http://clinicaltrials.gov/ct2/show/NCT01103284). Completion of patient recruitment is anticipated by the 1st half of 2012 (Press release, Andromeda, 22 Nov 2011, http://www.andromedabio.com/page.php?pageID=69). Final data is expected in 2014 or by the end of 2015 (Company presentation, Evotec, 8 Feb 2012, Page 16, http://evotec.sissy.bgcc.at/uplo ... on_February_e.pdf). First Phase III data are expected in 2012 (Press release, Evotec, 12 May 2011, http://www.evotec.com/archive/en ... e-business/2155/1). It is in an extension study in Israel, S Africa (submitted for approval) and Europe (planned) in patients who completed 2yr of treatment in the previous Phase III trial and still maintain beta cell function (Company Web Page, Anrdromeda, 10 Feb 2009). Phase II Data are expected in 2012 (Company Web Page, Evotec, 25 May 2011, http://www.evotec.com/articles/e ... -partnerships/4/6). In combined analysis from Phase II trials, DiaPep277 results in a dose-dependent improvement in C-peptide levels. DiaPep77 1mg q 3mth was the most effective regimen (10th BIO-Europe (Cologne), 2004). Evotec In a terminated Phase II trial in Germany, Italy and the UK, and a US Phase II trial, in LADA patients, there were no safety issues in >250 patients (2nd Qtr Res, Aventis, 2002; 10th BIO-Europe (Cologne), 2004; ClinicalTrials.gov Web Page, 13 Feb 2007, NCT00058981). Diabetes, Type 1 Sanofi Six Phase II studies in newly diagnosed and established adult Type 1 diabetics and 2 clinical trials in children with newly diagnosed Type 1 diabetes were conducted (BIO 2003 (Washington, DC); 2nd Qtr Res, Aventis, 2002; 10th BIO-Europe (Cologne), 2004). Diabetes, Type 1 Evotec In a placebo-controlled, randomized, double-blind, 10mth Phase II trial in 35 recently-diagnosed Type 1 diabetics, DiaPep227 at mth 0, 1 and 6 + daily insulin injections resulted in C-peptide concentration increases from 0.66 to 0.93nM cf a decrease of 1.12 to 0.26nM with placebo. The need for insulin injections increased over 10mth from 0.37 to 0.67U/kg daily in the placebo group cf an increase from 0.34 to 0.43U/kg in the treated group. DiaPep227 arrested disease progression and prevented further destruction of insulin-producing pancreatic β-cells (Press releases, Peptor, 22 Nov 2001 & 14 Jan 2002). Phase I It was well tolerated in Phase I trials (BIO 2003 (Washington, DC)). |
2樓2012-05-04 09:24:38
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時(shí)
- 蟲號(hào): 674536
- 注冊(cè): 2008-12-14
- 性別: GG
- 專業(yè): 無(wú)神論
- 管轄: 人文社科
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★
eileenshen: 金幣+8, ★★★很有幫助, 非常感謝你的幫助 2012-05-04 14:50:01
eileenshen: 金幣+8, ★★★很有幫助, 非常感謝你的幫助 2012-05-04 14:50:01
|
http://g.zhubajie.com/urllink.php?id=12300407koak830c54h3e2qa pharmaprojects報(bào)告 |
3樓2012-05-04 09:26:55
4樓2012-05-06 16:51:07
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 303求調(diào)劑 +4 | DLkz1314. 2026-03-30 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 求調(diào)劑 +7 | 研研，接電話 2026-03-24 | 8/400 |
|
|
|
[考研] 材料工程專碩求調(diào)劑 +6 | hyl3153942 2026-03-29 | 6/300 |
|
|
|
[考研] 一志愿南開大學(xué)0710生物學(xué)359求調(diào)劑 +5 | 兔兔兔111223314 2026-03-29 | 5/250 |
|
|
|
[考研] 337求調(diào)劑 +6 | 《樹》 2026-03-29 | 6/300 |
|
|
|
[考研] 289求調(diào)劑 +5 | BrightLL 2026-03-29 | 5/250 |
|
|
|
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +5 | hanamiko 2026-03-29 | 5/250 |
|
|
|
[考研] 332求調(diào)劑 +4 | @MZB382400 2026-03-28 | 4/200 |
|
|
|
[考研] 343求調(diào)劑 +5 | 愛羈絆 2026-03-28 | 5/250 |
|
|
|
[考研] 283求調(diào)劑 +3 | A child 2026-03-28 | 3/150 |
|
|
|
[考研] 085602 化工專碩 338分 求調(diào)劑 +12 | 路癡小琪 2026-03-27 | 12/600 |
|
|
|
[考研] 394求調(diào)劑 +3 | 好事多磨靜候佳?/a> 2026-03-26 | 5/250 |
|
|
|
[考研] 347求調(diào)劑 +3 | 山頂見α 2026-03-25 | 3/150 |
|
|
|
[考研] 085600，材料與化工321分，求調(diào)劑 +9 | 大饞小子 2026-03-27 | 9/450 |
|
|
|
[考研] 305求調(diào)劑 +5 | 哇盧卡庫(kù) 2026-03-26 | 5/250 |
|
|
|
[考研] 考研調(diào)劑 +9 | 小蠟新筆 2026-03-26 | 9/450 |
|
|
|
[考研] 材料專碩 335 分求調(diào)劑 +4 | 拒絕冷暴力 2026-03-25 | 4/200 |
|
|
|
[考研] 材料專碩找調(diào)劑 +5 | 哈哈哈吼吼吼哈 2026-03-23 | 5/250 |
|
|
|
[考研] 化工專碩求調(diào)劑 +3 | question挽風(fēng) 2026-03-24 | 3/150 |
|
|
|
[考研] 材料專碩331求調(diào)劑 +4 | 鮮當(dāng)牛 2026-03-24 | 4/200 |
|